use Oversight Panel to Assess Efficacy of Vaccine Injury Reporting, Compensation Systems

The continued fallout from the COVID-19 vaccines’ introduction has raised questions about the effectiveness of the United States’ existing vaccine injury reporting and compensation systems.

On Feb. 15, a panel of the House Oversight and Accountability Committee will hold a hearing to examine those systems and how they might be improved for future victims. Witnesses will include officials at the U.S. Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and the Health Resources and Services Administration (HRSA).

“Vaccine safety systems were designed to protect public health. Unfortunately, the COVID-19 pandemic—and resulting vaccine mandates—appear to have exceeded the capabilities of these systems,” Subcommittee Chairman Brad Wenstrup (R-Ohio) said in announcing the hearing on Feb.

without having a sufficient system in place to protect and compensate individuals who were potentially harmed. This hearing is an important step to increase vaccine transparency and to ensure that victims of future vaccine injuries are properly compensated,” he said.

https://sway.cloud.microsoft/vLogYHMzHXg77pBh
https://sway.cloud.microsoft/oZZqBXIIJDQh71Ip
https://sway.cloud.microsoft/nZKYcTz9Ho1DH6Xq

Since 1990, the nation’s early warning system for reporting vaccine injuries has been the Vaccine Adverse Event Reporting System (VAERS). The system is co-managed by the FDA and CDC, but anyone can submit a report, regardless of medical expertise.

And report they have. As of Jan. 26, more than 1.6 million adverse event reports have been submitted to VAERS in connection with the COVID-19 vaccines, according to OpenVAERS, a private organization that compiles and publishes VAERS data online.

Documents obtained through a Freedom of Information Act (FOIA) request also show that the sheer volume of those reports—though downplayed by health agencies—surprised officials in the months following the first vaccines’ rollout in December 2020.

RELATED STORIES

Leave a Reply

Your email address will not be published. Required fields are marked *